Independent directory Public ClinicalTrials.gov records United States
ClinicalTrials.gov record
Completed Phase 3 Interventional Results available

Efficacy and Safety of Faster-acting Insulin Aspart Compared to NovoRapid® Both in Combination With Insulin Degludec in Children and Adolescents With Type 1 Diabetes

ClinicalTrials.gov ID: NCT02670915

Public ClinicalTrials.gov record NCT02670915. Field values are reproduced from the official study page; the official ClinicalTrials.gov record remains the source of truth for eligibility, enrollment, and contact information.

ClinicalTrials.gov public records Last synced May 6, 2026, 7:31 PM EDT

Data is sourced from official ClinicalTrials.gov public API records. Always review the official ClinicalTrials.gov record for the latest information.

Study identification

NCT ID
NCT02670915
Recruitment status
Completed
Study type
Interventional
Phase
Phase 3
Lead sponsor
Novo Nordisk A/S
Industry
Enrollment
834 participants

Conditions and interventions

Interventions

  • Faster-acting insulin aspart Drug
  • insulin aspart Drug
  • insulin degludec Drug

Drug

Eligibility (public fields only)

Age range
1 Year to 17 Years
Sex
All
Healthy volunteers
Healthy volunteers not accepted

This page does not interpret eligibility. Detailed inclusion and exclusion criteria are on the official ClinicalTrials.gov record.

Study timeline

Start date
May 3, 2016
Primary completion
Feb 4, 2018
Completion
Mar 2, 2018
Last update posted
Jun 4, 2019

2016 – 2018

United States locations

U.S. sites
38
U.S. states
22
U.S. cities
35
Facility City State ZIP Site status
Novo Nordisk Investigational Site Phoenix Arizona 85053
Novo Nordisk Investigational Site Tucson Arizona 85724
Novo Nordisk Investigational Site Long Beach California 90806
Novo Nordisk Investigational Site Los Angeles California 90027
Novo Nordisk Investigational Site Sacramento California 95821
Novo Nordisk Investigational Site Ventura California 93003
Novo Nordisk Investigational Site Aurora Colorado 80045
Novo Nordisk Investigational Site Gainesville Florida 32608
Novo Nordisk Investigational Site Jacksonville Florida 32207
Novo Nordisk Investigational Site Orlando Florida 32806
Novo Nordisk Investigational Site Tallahassee Florida 32308
Novo Nordisk Investigational Site Tampa Florida 33612
Novo Nordisk Investigational Site Atlanta Georgia 30339
Novo Nordisk Investigational Site Boise Idaho 83712
Novo Nordisk Investigational Site Idaho Falls Idaho 83404-7596
Novo Nordisk Investigational Site Springfield Illinois 62702
Novo Nordisk Investigational Site Lexington Kentucky 40503
Novo Nordisk Investigational Site Baltimore Maryland 21229
Novo Nordisk Investigational Site Boston Massachusetts 02215
Novo Nordisk Investigational Site Minneapolis Minnesota 55416
Novo Nordisk Investigational Site Minneapolis Minnesota 55455
Novo Nordisk Investigational Site Las Vegas Nevada 89128
Novo Nordisk Investigational Site Neptune City New Jersey 07753
Novo Nordisk Investigational Site Buffalo New York 14203
Novo Nordisk Investigational Site Mineola New York 11501
Novo Nordisk Investigational Site Raleigh North Carolina 27610
Novo Nordisk Investigational Site Fargo North Dakota 58122
Novo Nordisk Investigational Site Columbus Ohio 43205
Novo Nordisk Investigational Site Tulsa Oklahoma 74135
Novo Nordisk Investigational Site Philadelphia Pennsylvania 19104
Novo Nordisk Investigational Site Philadelphia Pennsylvania 19107
Novo Nordisk Investigational Site Pittsburgh Pennsylvania 15224
Novo Nordisk Investigational Site Sioux Falls South Dakota 57105
Novo Nordisk Investigational Site Amarillo Texas 79106
Novo Nordisk Investigational Site Austin Texas 78731
Novo Nordisk Investigational Site Dallas Texas 75231
Novo Nordisk Investigational Site Dallas Texas 75235
Novo Nordisk Investigational Site Salt Lake City Utah 84132

Site contact phone numbers, emails, and investigator names are intentionally not displayed here. Open the official ClinicalTrials.gov record for site contact information.

Non-U.S. locations

This page focuses on the U.S. directory. The official record also lists 117 non-U.S. sites.

About this trial record page

What this page shows
Public field values for ClinicalTrials.gov record NCT02670915, including study identification, conditions, interventions, eligibility (age, sex, healthy volunteer), timeline, and U.S. site list.
What this page does not do
No medical advice, eligibility judgments, treatment recommendations, study quality scoring, or AI-generated medical summaries. No site contact phone numbers, emails, or investigator names.
Where the data comes from
Sourced from the official ClinicalTrials.gov public API. The official record is the source of truth.
Last refresh
Last update posted Jun 4, 2019 · Synced May 6, 2026

Related: full search, browse by condition, browse by drug or therapy, browse by sponsor, browse by U.S. city.

Open the official record

The complete protocol, eligibility criteria, and contact information for NCT02670915 live on ClinicalTrials.gov.

View official ClinicalTrials.gov record →